摘要
目的探讨活化增视冲剂对增殖性玻璃体视网膜病变(PVR)防治作用的机制。方法将60只新西兰大白兔随机分为A组20只(40眼)、B组20只(40眼)、C组20只(40眼),A、B组采用兔眼玻璃体内注射同种异体巨噬细胞的方法建立PVR模型,C组不作任何处理。造模后第2天开始,A组予活化增视冲剂5 mL/kg灌胃(含活化增视剂生药0.25 g/mL)、2次/d,B、C组予温生理盐水5 mL/kg灌胃、2次/d。每周用间接眼底镜检查玻璃体、眼底,观察PVR的形成与发展情况。造模后第3、7、14、21、28天,A、B、C组各处死4只兔子,取双眼玻璃体液,ELISA检测玻璃体液中的IL-1β和TNF-α。结果在造模后第14、21、28天时A组2级以上PVR的发生率低于B组(P均<0.05)。造模后第7天,A组玻璃体中IL-1β、TNF-α的含量低于B组(P<0.05);在第14、21、28天,A组玻璃体中IL-1β、TNF-α的含量明显低于B组(P均<0.01)。结论活化增视冲剂可在PVR早期降低玻璃体内的IL-1β、TNF-α的含量,从而抑制玻璃体内细胞增生的启动、细胞的移行和增殖,预防PVR的发生发展。
Objuctive To study the curative and preventive effects and the mechanism of huohuazengshi (HHZS) medicinalgranules on proliferative vitreoretinopathy (PVR) in rabbits. Methods 60 rabbits ( 120 eyes) were randomly di- vided into HHZS group( A group), control group( B group) and blank group( C group), 20 rabbits(40 eyes) each group. Experimental PVR models were induced by injecting macrophage into vitreous, the formation and development of PVR was observed by indirect ophthalmoscope, the content of IL-1β and TNF-α from the vitreous were determined. Results Com- pared with B group, the content of IL-1β and TNF-α in A group was decreased in 7 days( P 〈 0.05 ) and decreased signifi- cantly in 14,21 and 28 d (P 〈0.01 ). The incidence of PVR above 2 grades in 14,21 and 28 days was lower than B group ( P 〈 0.05 ). Conclusions HHZS medieinalgranules can inhibit and cure the formation and development of PVR by de- creasing the content of IL-1β and TNF-α in vitreous and inhibiting cell proliferation and migration.
出处
《山东医药》
CAS
2012年第22期12-14,共3页
Shandong Medical Journal
基金
山东省自然科学基金资助项目(Y2007C129)